BioCentury

8:09 PM GMT, Nov 8, 2018
This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.
Financial News

Cabaletta spins out of Penn with CAR T autoimmune therapy, $38M series A

University of Pennsylvania spinout Cabaletta Bio Inc. (Radnor, Pa.) emerged from stealth with an untranched $38 million series A to develop CAR T therapies

Read the full 243 word article

This article and the information contained in BioCentury's publications and services are solely for your own personal, non-transferable licensed use and cannot be shared with any other individuals. For information about adding subscribers to your account or obtaining article reprints, please contact support@biocentury.com.